5001842022-07-012022-09-305001842022-09-305001842022-03-315001842022-04-012022-09-305001842022-07-012022-09-30in-bse-fin:OtherExpenses1Member5001842022-04-012022-09-30in-bse-fin:OtherExpenses1Member5001842022-07-012022-09-30in-bse-fin:ReportableSegments1Member5001842022-07-012022-09-30in-bse-fin:ReportableSegments2Member5001842022-04-012022-09-30in-bse-fin:ReportableSegments1Member5001842022-04-012022-09-30in-bse-fin:ReportableSegments2Member5001842022-07-012022-09-30in-bse-fin:ReportableSegments1Member5001842022-07-012022-09-30in-bse-fin:ReportableSegments2Member5001842022-04-012022-09-30in-bse-fin:ReportableSegments1Member5001842022-04-012022-09-30in-bse-fin:ReportableSegments2Member5001842022-07-012022-09-30in-bse-fin:ReportableSegments1Member5001842022-09-30in-bse-fin:ReportableSegments1Member5001842022-07-012022-09-30in-bse-fin:ReportableSegments2Member5001842022-09-30in-bse-fin:ReportableSegments2Member5001842022-07-012022-09-30in-bse-fin:ReportableSegments1Member5001842022-09-30in-bse-fin:ReportableSegments1Member5001842022-07-012022-09-30in-bse-fin:ReportableSegments2Member5001842022-09-30in-bse-fin:ReportableSegments2Member5001842022-07-012022-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15001842022-07-012022-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25001842022-04-012022-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15001842022-04-012022-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss2iso4217:INRiso4217:INRxbrli:shares500184HSCLNAINE019C01026Himadri Speciality Chemical LtdEquity2022-04-012022-03-312022-10-292022-10-21INRCroresHalf yearlyMulti segment2022-10-2912:30:002022-10-2917:00:00trueCash Flow IndirectNot applicable2022-07-012022-09-30UnauditedStandalone10589100000819000001067100000097285000000-1428200000257800000199300000125400000113280000010015600000655400000-30000000035540000062000000210000064100000029130000000002913000004406000007319000000041930000010.690.69000.690.69Statement of Cash Flows has been prepared under the indirect method as set out in Ind AS 7 "Statement of Cash Flows". <BR> <BR> NOTES:- <BR> (2) The above unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 29 October 2022. A Limited Review of these standalone financial results for the quarter and six months ended 30 September 2022 has been carried out by the Statutory Auditors, as required under Regulation 33 of SEBI (LODR) Regulations, 2015. <BR> <BR> (3) Other expenses includes foreign exchange fluctuation loss (net) of Rs 5.54 crores for the quarter ended 30 September 2022, Rs 13.63 crores for the quarter ended 30 June 2022, Rs 3.46 crores for the quarter ended 30 September 2021, Rs 19.17 crores for the six months ended 30 September 2022, Rs 3.72 crores for the six months ended 30 September 2021 and Rs 7.67 crores for the year ended 31 March 2022, on standalone basis. <BR> <BR> Finance cost includes exchange difference regarded as an adjustment to borrowing costs in accordance with Ind AS 23, of Rs 6.13 crores for the quarter ended 30 September 2022, Rs 4.55 crores for the quarter ended 30 June 2022, Re (0.28) crore for the quarter ended 30 September 2021, Rs 10.68 crores for the six months ended 30 September 2022, Rs 1.86 crores for the six months ended 30 September 2021 and Rs 2.24 crores for the year ended 31 March 2022, on standalone basis. <BR> <BR> (4) Based on the guiding principles given in Ind AS 108 on 'Operating Segments', the Company's business activity falls within two operating segments, namely: <BR> (a) Carbon materials and chemicals, and <BR> (b) Power <BR> ` <BR> (5) The Company has issued and allotted 7,25,50,000 warrants, each convertible into one Equity Share of Re 1/- each, on Preferential allotment basis at an issue price of Rs 70/- per warrant, to the Promoter/ Promoter Group of the Company and certain identified non-promoter persons / entity, upon receipt of 25% of the issue price (i.e. Rs 17.50 per warrant) as warrant subscription money. Balance 75% of the issue price (i.e. Rs 52.50 per warrant) shall be payable within 18 months from the date of allotment i.e.22 August 2022, at the time of exercising the option to apply for fully paid-up equity share of Re 1/- each of the Company, against each warrant held by the warrant holder. <BR> <BR> (6) The Company has considered the possible risk that may result from the pandemic relating to COVID-19 and expects to recover the carrying amount of all its assets including inventories, receivable, investments and other financial and non-financial assets in the ordinary course of business based on the internal and external information available upto the date of approval of these standalone financial results. The Company is continuously monitoring for any material changes in future economic conditions. <BR> <BR> (7) Earnings per share is not annualised for the quarter ended 30 September 2022, 30 June 2022, 30 September 2021, six months ended 30 September 2022 and 30 September 2021. <BR> <BR> (8) The Board, at its meeting held on 8 July 2022, took on record that the promoters of the Company entered into the Family Settlement Agreement. Pursuant to the family settlement agreement, the Company entered into a non-compete agreement at a consideration of Rs 30 crores with the outgoing promoters. Accordingly, necessary accounting impact of the same has been given effect in the current quarter. <BR> <BR> (9) The figures of the corresponding previous periods/year have been regrouped/reclassified, wherever necessary, to conform to the classification for the current quarter and six months ended 30 September 2022. <BR> 2022-04-012022-09-30UnauditedStandalone210555000009750000021153000000177522000000-11353000004859000003253000002460000002340800000200149000001138100000-30000000083810000014620000011300000157500000068060000000006806000002799000009605000000041930000011.621.62001.621.62Other Expenses1132800000Other Expenses234080000014359300000855100000021870000014911000001006000001000000020530000018070000009150000014910000017480700000738570000006157900000262070000031143000001550000014750000012055900000018550000002129660000038777300000419300000197719000002019120000020191200000707500000016800000724300000453000008245000000015941000001240660000014519000003705000001422900000027429000002010000000169920000001858610000038777300000(a) Carbon materials and Chemicals10536500000(B) Power247200000(a) Carbon materials and Chemicals20950700000(B) Power51680000010783700000214675000001946000004120000001058910000021055500000(a) Carbon materials and Chemicals616100000(B) Power212100000(a) Carbon materials and Chemicals1105400000(B) Power4522000008282000001557600000199300000325300000273500000394200000355400000838100000(a) Carbon materials and Chemicals30066000000(B) Power117720000031243200000753410000038777300000(a) Carbon materials and Chemicals4545300000(B) Power4240000045877000001399840000018586100000Other unallocable expenses net of unallocable income includes other income, foreign exchange loss/ (gain) (net), and exceptional items fully unallocable325300000338300000-10431000000-100000057000000-7752000000-6281600000019375000000246000000000-1340000002104000000442000000000000-5095300000-42572000000001640000000-44212000000000000040600000542900000149560000014900000000000000000000000139000000-2197200000-268000000000710000012696000000000710420000016730000001170000001927000000-600000800860000090740000040000090780000017129000002620700000Remeasurements of the net defined benefit plan-500000Net gain/ (loss) on investment in equity instruments accounted at fair value571200000570700000Remeasurements of the net defined benefit plan-1000000Net gain/ (loss) on investment in equity instruments accounted at fair value3626000003616000001301000008170000000